Cellectar Biosciences, Inc. is a clinical stage biopharmaceutical company with the potential to change the landscape of cancer treatment. With its unique phospholipid drug conjugates (PDCs), the company has developed a way to specifically target cancer cells in the body with minimal toxicity, creating new treatment options for patients.
"The third quarter proved to be highly productive for Cellectar with CLR 131 receiving FDA Fast Track Designation for DLBCL and Orphan Drug Designation for multiple myeloma from the European Commission. In addition, we presented incremental positive data at international scientific conferences. We continue to anticipate data from our ongoing clinical studies by the end of this year and in early 2020." - Jim Caruso, CEO of Cellectar Biosciences
3 Ongoing Clinical Trials
Cellectar Biosciences' lead PDC radiotherapeutic, known as CLR 131 is the subject of 3 ongoing clinical trials. In these trials, CLRB is targeting relapsed or refractory hematologic malignancies including multiple myeloma, and pediatric malignancies.
Key Recent Achievements
Recently, CLR 131 received a second Fast Track Designation from the FDA and Orphan Drug Designation from the European Commission. These key achievements will provide Cellectar with additional regulatory support and speed up potential approval. The Orphan Drug Designation provides ten years of market exclusivity for the treatment of multiple myeloma.
Multiple Catalysts Ahead
Cellectar Biosciences has multiple catalysts for investors to look forward to in the coming months. With 3 ongoing clinical trials, investors can look forward to data readouts, regulatory updates and more. Learn more about these catalysts by checking Cellectar's product pipeline.
Radiotherapeutic Market Opportunity
It is estimated by Research & Markets that the radiotherapeutic market will generate $9.3 billion in 2020 as the market continues to grow with a CAGR of 10.2% through 2025.
Dive Into The Details
Learn more about this compelling opportunity by diving into the Cellectar Biosciences Fact Sheet.
Check Out The Investor Presentation
Learn more about PDC compounds, strides that CLRB is making, and more with the investor deck below!
Read CLRB's SEC Filings
Click the button to the right to see Cellectar Biosciences' SEC filings.
Get FREE Stock Alerts
Sign up for our FREE mailing list below to receive real-time alerts sent directly to your inbox!
Copyright © 2019 Alpha Stock News. All rights reserved
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Cellectar Biosciences, CNA Finance has been hired for a period beginning on 12/1/19 and ending on 12/31/19 to conduct digital advertising and marketing and publicly disseminate information about CLRB via Websites and Email. We have been paid an upfront payment of fifteen thousand dollars via bank wire transfer. We own zero shares of Cellectar Biosciences. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Cellectar Biosciences has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.